Remove Alliance partnership Remove Biopharma Remove Life science Related Topics
article thumbnail

Biopharma M&A in 2024 β€” Five Considerations for Deal Execution

Vantage Partners

Analysis from EY found that life sciences M&A spend was up 34% last year relative to 2022, despite a reduction in deal volume. It’s no great secret that M&A activity in bipoharma has been on the rise over the past 12 months.

article thumbnail

Reflections on 2020 ASAP BioPharma Conference: The right mindset is more important than ever

Vantage Partners

Overview The 2020 ASAP BioPharma conference came to a close a month ago and marked another year of bringing together talented and thoughtful strategic alliance professionals to share and reflect on their experiences in this field.